[Induction therapy with interferon alfa-2a in compensated hepatitis C virus-related cirrhosis. Randomized, multicenter study] (Q74170792)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

[Induction therapy with interferon alfa-2a in compensated hepatitis C virus-related cirrhosis. Randomized, multicenter study] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference

Ramon Planas

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Juan Carlos Quer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Jaime Enríquez

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Josep Maria Barrera

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Blai Dalmau

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Teresa Casanovas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Josep Maria Viver

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Miquel Torres

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Jaume Boadas

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Ricart Solà

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Rosa Durández

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Cristóbal Richart

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Miquel Bruguera

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 May 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

641-644

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis C: the clinical spectrum of disease

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Hepatitis C: somber views of natural history and optimistic views of interferon treatment?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Therapy of hepatitis C: patients with cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Coinfection with hepatitis G virus in chronic hepatitis C. Response to treatment with interferon alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Clinical Pharmacokinetics of Interferons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Treatment of cirrhotic hepatitis C virus patients with daily doses of interferon-alpha 2a.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Peginterferon alfa-2a in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Factors predictive of a beneficial response to therapy of hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2802%2972483-4

10.1016/S0025-7753(02)72483-4

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12028899%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference